SAB Biotherapeutics, Inc.

Historical 13F Holders

Symbol
SABS
CUSIP
78397T202
All holders as of
Q3 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 78397T202 since 12/18/2024, largest first.

Filer % of Class Filed
Vivo Opportunity Fund Holdings, L.P. 13G/A
10.0% 11/16/2026
Event 9/30/2026
RA Capital Management, L.P. 13D/A
9.9% 8/10/2026
Event 8/6/2026
Commodore Capital LP 13G/A
9.9% 8/14/2026
Event 6/30/2026
Biotechnology Value Fund L P 13G/A
9.1% 2/17/2026
Event 12/31/2025
Caligan Partners LP 13G/A
8.8% 8/14/2026
Event 6/30/2026
Adage Capital Management, L.P. 13G
8.4% 8/12/2026
Event 6/30/2026
Balyasny Asset Management L.P. 13G/A
7.9% 11/16/2026
Event 9/30/2026
Perceptive Advisors LLC 13G/A
7.3% 8/14/2026
Event 6/30/2026
Woodline Partners LP 13G/A 5.7% 11/16/2026
Event 9/30/2026
Millennium Management LLC 13G
5.1% 5/1/2026
Event 4/24/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (1)
RTW Investments, LP 13G/A
3.2% 2/17/2026
Event 12/31/2025

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 103 78.3 M $248M
2026 Q2 88 68.4 M $267M
2026 Q1 80 69.2 M $265M
2025 Q4 49 36.3 M $136M
2025 Q3 34 28.0 M $56.3M
2025 Q2 26 1.92 M $3.37M
2025 Q1 27 2.21 M $2.99M
2024 Q4 26 2.63 M $10.1M
2024 Q3 26 3.14 M $8.48M
2024 Q2 23 3.13 M $9.69M
2024 Q1 25 3.34 M $15.2M
2023 Q4 3 8.79 M $6.06M